CytomX Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

• CytomX Therapeutics Inc CTMX.OQ reported quarterly breakeven results​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -8 cents. The mean expectation of seven analysts for the quarter was for a loss of 8 cents per share. Wall Street expected results to range from -14 cents to -2 cents per share.

• Revenue fell 25.7% to $18.66 million from a year ago; analysts expected $14.78 million.

• CytomX Therapeutics Inc's reported EPS for the quarter was breakeven results​.

• The company reported a quarterly loss of $154 thousand.

• CytomX Therapeutics Inc shares had fallen by 4.4% this quarter and gained 110.7% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 270.4% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for CytomX Therapeutics Inc is $5.50, about 61.8% above its last closing price of $2.10

This summary was machine generated from LSEG data August 8 at 04:03 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)